This indicates that anti‐IL‐4Rα therapies may be suitable for therapeutic treatment of acute allergic disease patients and possibly prophylactic intervention in asymptomatic, but sensitized patients, who represent 50%‐60% of asthma patients44, 45 and are highly at risk of developing asthma or eczema.46, 47. Here, IL4R is linked to Eczematoid dermatitis.